Blockbuster drug from CT co. on Medicare list for price checks
The Biden administration included Boehringer Ingelheim's Jardiance drug among those that will be subject to price checks, with Medicare sales at $7 billion. |!| Torrington
The Biden administration included Boehringer Ingelheim's Jardiance drug among those that will be subject to price checks, with Medicare sales at $7 billion. |!| Torrington